Why osteonecrosis of the jaw after bisphosphonates treatment is more frequent in multiple myeloma than in solid tumors

Journal of Oral and Maxillofacial Surgery

Volumn 64, Issue 6, 2006, Pages 995-996

  Delibasi, Tuncay ^a   Altundag, Kadri ^a   Kanlioglu, Yesim ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

BONE MARROW; BONE METASTASIS; BONE NECROSIS; BREAST CANCER; DRUG TOLERABILITY; DRUG USE; HUMAN; JAW; LETTER; MANDIBLE; MAXILLA; MORBIDITY; MULTIPLE MYELOMA; OSTEOCLAST; OSTEOPOROSIS; PLASMA CELL; RETROSPECTIVE STUDY; RISK FACTOR; SOLID TUMOR;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; JAW; JAW DISEASES; MULTIPLE MYELOMA; OSTEOCLASTS; OSTEONECROSIS;

EID: 33646587637     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2006.03.002     Document Type: Letter

References (2)

1. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates. Incidence and risk factors. J Clin Oncol 23 (2005) 8580
2. Durie B.G.M., Katz M., and Crowley J. Osteonecrosis of the jaws and bisphosphonates. N Engl J Med 353 (2005) 99